Takeda Pharmaceutical Co., Ltd.
0
0
0%

Financials

Income statement

Fiscal date 2025 2024 2023 2022
Total reported revenue 4.6T 4.3T 4.0T 3.6T
Cost of revenue 1.6T 1.4T 1.2T 1.1T
Gross profit 3.0T 2.8T 2.8T 2.5T
Operating expense
Research & development 730.2B 729.9B 633.3B 526.1B
Selling general and admin 1.1T 1.1T 997.3B 886.4B
Other operating expenses 37.0B 80.3B 55.4B 30.8B
Operating income 486.1B 321.0B 554.9B 546.0B
Non operating interest income
Income 19.6B 11.3B 5.5B 4.6B
Expense 137.3B 119.5B 117.0B 122.4B
Other income expense -169.3B -127.7B -56.4B -120.0B
Pretax income 175.1B 52.8B 375.1B 302.6B
Tax provision 66.9B -91.4B 58.1B 72.4B
Net income 108.1B 144.2B 317.0B 230.2B
Basic EPS 68.4 92.1 204.3 147.1
Diluted EPS 67.2 91.2 201.9 145.9
Basic average shares 1.6B 1.6B 1.6B 1.6B
Diluted average shares 1.6B 1.6B 1.6B 1.6B
EBITDA 1.2T 1.0T 1.2T 1.1T
Net income from continuing op. 108.1B 144.2B 317.0B 230.2B
Minority interests -215M -130M -21M -107M
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed
Main market opens in 16 hours 32 minutes

16:27
00:00
09:00
15:30
23:59

Trading Hours (Monday - Friday):

Main market
09:00 - 15:30
All times are displayed in the Asia/Tokyo timezone (JST, UTC+09:00).